State-of-the-Art Chemotherapy for Advanced Non-Small Cell Lung Cancer

Sakkaraiappan Ramalingam, Chandra Belani

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The treatment of advanced non-small cell lung cancer (NSCLC) has continued to evolve over recent years. We have moved from an era of therapeutic nihilism to optimism, largely because of the advent of the newer cytotoxic agents developed in the 1990s that have complemented the platinum compounds for treatment of advanced NSCLC. Doublet chemotherapy combinations have become the current standard of care for patients with advanced NSCLC who have a good performance status. For patients with poor performance status and the elderly, single-agent chemotherapy results in modest improvements in survival. Prolongation of survival and improved quality of life have also been shown with second-line chemotherapy for patients who are either refractory to or relapse following first-line chemotherapy. Noncytotoxic, molecularly targeted agents currently under various phases of development for the treatment of lung cancer will serve as the cornerstones for further innovations in the treatment of NSCLC.

Original languageEnglish (US)
Pages (from-to)68-74
Number of pages7
JournalSeminars in oncology
Volume31
Issue number1 SUPPL. 1
DOIs
StatePublished - Jan 1 2004

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Platinum Compounds
Therapeutics
Survival
Cytotoxins
Standard of Care
Combination Drug Therapy
Lung Neoplasms
Quality of Life
Recurrence

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Ramalingam, Sakkaraiappan ; Belani, Chandra. / State-of-the-Art Chemotherapy for Advanced Non-Small Cell Lung Cancer. In: Seminars in oncology. 2004 ; Vol. 31, No. 1 SUPPL. 1. pp. 68-74.
@article{9c981adabf5a4e7299e85b5910d38fb2,
title = "State-of-the-Art Chemotherapy for Advanced Non-Small Cell Lung Cancer",
abstract = "The treatment of advanced non-small cell lung cancer (NSCLC) has continued to evolve over recent years. We have moved from an era of therapeutic nihilism to optimism, largely because of the advent of the newer cytotoxic agents developed in the 1990s that have complemented the platinum compounds for treatment of advanced NSCLC. Doublet chemotherapy combinations have become the current standard of care for patients with advanced NSCLC who have a good performance status. For patients with poor performance status and the elderly, single-agent chemotherapy results in modest improvements in survival. Prolongation of survival and improved quality of life have also been shown with second-line chemotherapy for patients who are either refractory to or relapse following first-line chemotherapy. Noncytotoxic, molecularly targeted agents currently under various phases of development for the treatment of lung cancer will serve as the cornerstones for further innovations in the treatment of NSCLC.",
author = "Sakkaraiappan Ramalingam and Chandra Belani",
year = "2004",
month = "1",
day = "1",
doi = "10.1053/j.seminoncol.2003.12.017",
language = "English (US)",
volume = "31",
pages = "68--74",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 1",

}

State-of-the-Art Chemotherapy for Advanced Non-Small Cell Lung Cancer. / Ramalingam, Sakkaraiappan; Belani, Chandra.

In: Seminars in oncology, Vol. 31, No. 1 SUPPL. 1, 01.01.2004, p. 68-74.

Research output: Contribution to journalArticle

TY - JOUR

T1 - State-of-the-Art Chemotherapy for Advanced Non-Small Cell Lung Cancer

AU - Ramalingam, Sakkaraiappan

AU - Belani, Chandra

PY - 2004/1/1

Y1 - 2004/1/1

N2 - The treatment of advanced non-small cell lung cancer (NSCLC) has continued to evolve over recent years. We have moved from an era of therapeutic nihilism to optimism, largely because of the advent of the newer cytotoxic agents developed in the 1990s that have complemented the platinum compounds for treatment of advanced NSCLC. Doublet chemotherapy combinations have become the current standard of care for patients with advanced NSCLC who have a good performance status. For patients with poor performance status and the elderly, single-agent chemotherapy results in modest improvements in survival. Prolongation of survival and improved quality of life have also been shown with second-line chemotherapy for patients who are either refractory to or relapse following first-line chemotherapy. Noncytotoxic, molecularly targeted agents currently under various phases of development for the treatment of lung cancer will serve as the cornerstones for further innovations in the treatment of NSCLC.

AB - The treatment of advanced non-small cell lung cancer (NSCLC) has continued to evolve over recent years. We have moved from an era of therapeutic nihilism to optimism, largely because of the advent of the newer cytotoxic agents developed in the 1990s that have complemented the platinum compounds for treatment of advanced NSCLC. Doublet chemotherapy combinations have become the current standard of care for patients with advanced NSCLC who have a good performance status. For patients with poor performance status and the elderly, single-agent chemotherapy results in modest improvements in survival. Prolongation of survival and improved quality of life have also been shown with second-line chemotherapy for patients who are either refractory to or relapse following first-line chemotherapy. Noncytotoxic, molecularly targeted agents currently under various phases of development for the treatment of lung cancer will serve as the cornerstones for further innovations in the treatment of NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=1242318822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242318822&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2003.12.017

DO - 10.1053/j.seminoncol.2003.12.017

M3 - Article

C2 - 14981583

AN - SCOPUS:1242318822

VL - 31

SP - 68

EP - 74

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 1

ER -